Oblimersen

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Antisense drug that specifically prevents the synthesis of proteins in the cell.

Pharmacodynamics (Effect)This section has been translated automatically.

Antisense molecules are chemically modified oligonucleotides and contain the complementary genetic information of a gene. They bind tightly to the messenger RNA of the gene, which prevents the translation thus the conversion into a protein in the ribosomes. In oblimersen, the gene was selected for the Bcl-2 protein, a protein produced by tumour cells, which thus prevents apoptosis. Oblimersen is therefore used in combination with chemotherapy.

Field of application/useThis section has been translated automatically.

For malignant melanoma, the results in studies have been disappointing so far. According to studies effective in chemotherapy for chronic lymphatic leukemia (CLL).

Undesirable effectsThis section has been translated automatically.

Common: thrombocytopenia. Rarely: tumor lysis syndrome.

PreparationsThis section has been translated automatically.

Genasense

LiteratureThis section has been translated automatically.

  1. Hauschild A et al (2008) systemic therapy of melanoma. Current clinical studies. dermatologist 59: 484-492

Authors

Last updated on: 29.10.2020